{"id":"W4220987969","doi":"10.1158/1538-7445.sabcs21-ot1-14-01","title":"Abstract OT1-14-01: Zanidatamab in combination with ALX148 in advanced human epidermal growth factor receptor 2 (HER2)-expressing cancers, including breast cancer: A phase 1b/2, multicenter, open-label, dose-finding and cohort-expansion study (ZWI-ZW25-204)","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Medicine; Breast cancer; Cancer; Trastuzumab; Antibody; Metastatic breast cancer; Combination therapy; Oncology; Cancer research; Phases of clinical research; Immune system; CD47; Internal medicine; Chemotherapy; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009893926,0.001550972,0.00165367,0.0005852911,0.0004030329,0.001011062,0.001023561,0.001339293,0.003884338],"category_scores_gemma":[0.0004310251,0.0005700155,0.001167468,0.0003750546,0.000856366,0.0007648848,0.000335873,0.003344261,0.001188223],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001018587,"about_ca_system_score_gemma":0.001780652,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001666231,"about_ca_topic_score_gemma":0.003628347,"domain_scores_codex":[0.9996796,0.0001145524,0.00001905856,0.00005881651,0.00004206185,0.00008598762],"domain_scores_gemma":[0.9996208,0.00003790573,0.0000594042,0.00003047514,0.00002434832,0.0002270075],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5342424,0.1300758,0.006000647,0.001014618,0.001834568,0.0005017572,0.0003038856,0.002992061,0.164581,0.0004614757,0.01123435,0.1467575],"study_design_scores_gemma":[0.4516701,0.5147984,0.01182703,0.00003606702,0.0006492117,0.0003762613,0.00005539495,0.001463986,0.01416225,0.0001386266,0.004776814,0.00004591137],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9931931,0.001385039,0.000417772,0.0004106416,0.0001399499,0.001274114,0.001408812,0.0001509069,0.001619631],"genre_scores_gemma":[0.9855146,0.00184183,0.001579245,0.0007596106,0.0001496286,0.00116413,0.003701199,0.00005051057,0.005239171],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003884338,"threshold_uncertainty_score":0.01299441,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1446286612492151,"score_gpt":0.4732179216635033,"score_spread":0.3285892604142883,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}